Page 1093 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 60 Myelodysplastic Syndromes 969.e7

277. Pagliuca A, Layton DM, Manoharan A, et al: Myelofibrosis in primary 302. Kornberg A, Goldfarb A: Preleukemia manifested by hemolytic anemia
myelodysplastic syndromes: a clinico-morphological study of 10 cases. with pyruvate-kinase deficiency. Arch Intern Med 146(4):785–786,
Br J Haematol 71(4):499–504, 1989. 1986.
278. Nangalia J, Green TR: The evolving genomic landscape of myelo- 303. Hast R: Sideroblasts in myelodysplasia: their nature and clinical signifi-
proliferative neoplasms. Hematology Am Soc Hematol Educ Program cance. Scand J Haematol Suppl 45:53–55, 1986.
2014(1):287–296, 2014. 304. Steensma DP, Higgs DR, Fisher CA, et al: Acquired somatic ATRX
279. Steensma DP, Heptinstall KV, Johnson VM, et al: Common trouble- mutations in myelodysplastic syndrome associated with alpha thalas-
some symptoms and their impact on quality of life in patients with semia (ATMDS) convey a more severe hematologic phenotype than
myelodysplastic syndromes (MDS): results of a large internet-based germline ATRX mutations. Blood 103(6):2019–2026, 2004.
survey. Leuk Res 32(5):691–698, 2008. 305. Annino L, Di Giovanni S, Tentorì L, et al: Acquired hemoglobin H
280. Pomeroy C, Oken MM, Rydell RE, et al: Infection in the myelodys- disease in a case of refractory anemia with excess of blasts (RAEB) evolv-
plastic syndromes. Am J Med 90(3):338–344, 1991. ing into acute nonlymphoid leukemia. Acta Haematol 72(1):41–44,
281. Raman B, Van Slyck E, Riddle J, et al: Platelet function and structure 1984.
in myeloproliferative disease, myelodysplastic syndrome, and secondary 306. French Registry of Acute Leukemia and Myelodysplastic Syndromes:
thrombocytosis. Am J Clin Pathol 647:91, 1989. Age distribution and hemogram analysis of the 4496 cases recorded
282. Avivi I, Rosenbaum H, Levy Y, et al: Myelodysplastic syndrome and during and classified according to criteria FAB, Groupe Francais de
associated skin lesions: a review of the literature. Leuk Res 23(4):323– Morphologie Hematologique. Cancer 60:1982–1983, 1987. 1385.
330, 1999. 307. Cech P, Markert M, Perrin LH: Partial myeloperoxidase deficiency in
283. Rochet NM, Chavan RN, Cappel MA, et al: Sweet syndrome: clinical preleukemia. Blut 47(1):21–30, 1983.
presentation, associations, and response to treatment in 77 patients. 308. Prodan M, Tulissi P, Perticarari S, et al: Flow cytometric assay for the
J Am Acad Dermatol 69(4):557–564, 2013. evaluation of phagocytosis and oxidative burst of polymorphonuclear
284. Ten Oever J, Kuijper PHM, Kuijpers ALA, et al: Complete remission leukocytes and monocytes in myelodysplastic disorders. Haematologica
of MDS RAEB following immunosuppressive treatment in a patient 80(3):212–218, 1995.
with Sweet’s syndrome. Neth J Med 67(8):347–350, 2009. 309. Ruutu P: Granulocyte function in myelodysplastic syndromes. Scand J
285. Jo T, Horio K, Migita K: Sweet’s syndrome in patients with MDS and Haematol Suppl 45:66–70, 1986.
MEFV mutations. N Engl J Med 372(7):686–688, 2015. 310. Schanz J, Tüchler H, Solé F, et al: New comprehensive cytogenetic
286. Srivastava M, Rencic A, Nousari HC: A rapidly expanding ulcer. scoring system for primary myelodysplastic syndromes (MDS) and
Myelodysplastic syndrome-associated (paraneoplastic) pyoderma gan- oligoblastic acute myeloid leukemia after MDS derived from an inter-
grenosum. Arch Dermatol 139(4):531–536, 2003. national database merge. J Clin Oncol 30(8):820–829, 2012.
287. Duguid JK, Mackie MJ, McVerry BA: Skin infiltration associated with 311. Tricot G, De Wolf-Peeters C, Vlietinck R, et al: Bone marrow histology
chronic myelomonocytic leukaemia. Br J Haematol 53(2):257–264, in myelodysplastic syndromes. II. Prognostic value of abnormal localiza-
1983. tion of immature precursors in MDS. Br J Haematol 58(2):217–225,
288. Enright H, Miller W: Autoimmune phenomena in patients with 1984.
myelodysplastic syndromes. Leuk Lymphoma 24(5–6):483–489, 1997. 312. Della Porta MG, Malcovati L, Boveri E, et al: Clinical relevance of
289. George S, Newman E: Seronegative inflammatory arthritis in the bone marrow fibrosis and CD34-positive cell clusters in primary
myelodysplastic syndromes. Semin Arthritis Rheum 21:345–354, myelodysplastic syndromes. J Clin Oncol 27(5):754–762, 2009.
1992. 313. Williamson PJ, Oscier DG, Mufti GJ, et al: Pyogenic abscesses in the
290. Green AR, Shuttleworth D, Bowen DT, et al: Cutaneous vasculitis myelodysplastic syndrome. BMJ 299(6695):375–376, 1989.
in patients with myelodysplasia. Br J Haematol 74(3):364–365, 314. Rasi V, Lintula R: Platelet function in the myelodysplastic syndromes.
1990. Scand J Haematol Suppl 45:71–73, 1986.
291. Tsuji G, Maekawa S, Saigo K, et al: Dermatomyositis and myelo- 315. Girtovitis FI, Ntaios G, Papadopoulos A, et al: Defective platelet aggre-
dysplastic syndrome with myelofibrosis responding to methotrexate gation in myelodysplastic syndromes. Acta Haematol 118(2):117–122,
therapy. Am J Hematol 74(3):175–178, 2003. 2007.
292. Enright H, Jacob HS, Vercellotti G, et al: Paraneoplastic autoimmune 316. Zeidman A, Sokolover N, Fradin Z, et al: Platelet function and its
phenomena in patients with myelodysplastic syndromes: response to clinical significance in the myelodysplastic syndromes. Hematol J
immunosuppressive therapy. Br J Haematol 91(2):403–408, 1995. 5(3):234–238, 2004.
293. Heo S-W, Cho K-H, Ryu J-I, et al: A case of relapsing polychondritis 317. Szpurka H, Tiu R, Murugesan G, et al: Refractory anemia with ringed
associated with myelodysplastic syndrome with erythroid hypoplasia/ sideroblasts associated with marked thrombocytosis (RARS-T), another
aplasia. Korean J Intern Med 18(4):251–254, 2003. myeloproliferative condition characterized by JAK2 V617F mutation.
294. Steurer M, Fritsche G, Tzankov A, et al: Large-vessel arteritis and Blood 108(7):2173–2181, 2006.
myelodysplastic syndrome: report of two cases. Eur J Haematol 318. Kuriyama K, Tomonaga M, Matsuo T, et al: Diagnostic significance of
73(2):128–133, 2004. detecting pseudo-Pelger-Huët anomalies and micro-megakaryocytes in
295. Saitoh T, Murakami H, Uchiumi H, et al: Myelodysplastic syndromes myelodysplastic syndrome. Br J Haematol 63(4):665–669, 1986.
with nephrotic syndrome. Am J Hematol 60(3):200–204, 1999. 319. Queisser W, Queisser U, Ansmann M, et al: Megakaryocyte poly-
296. Linman JW, Bagby GC: The preleukemic syndrome (hemopoietic ploidization in acute leukaemia and preleukaemia. Br J Haematol
dysplasia). Cancer 42(2 Suppl):854–864, 1978. 28(2):261–270, 1974.
297. Noel P, Solberg L, Jr: Myelodysplastic syndromes. Pathog Diagn Treat 320. Takagi S, Kitagawa S, Takeda A, et al: Natural killer-interferon system
Crit Rev Oncol 12(3):193–215, 1992. in patients with preleukaemic states. Br J Haematol 58(1):71–81, 1984.
298. Bowen DT, Jacobs A, Cotes PM, et al: Serum erythropoietin and eryth- 321. Kerndrup G, Meyer K, Ellegaard J, et al: Natural killer (NK)-cell activ-
ropoiesis in patients with myelodysplastic syndromes. Eur J Haematol ity and antibody-dependent cellular cytotoxicity (ADCC) in primary
44(1):30–32, 1990. preleukemic syndrome. Leuk Res 8(2):239–247, 1984.
299. Kushner J, Porter J, Olivieri N: Secondary iron overload. Hematology 322. Britanova OV, Putintseva EV, Shugay M, et al: Age-related decrease in
Am Soc Hematol Educ Program 47, 2001. TCR repertoire diversity measured with deep and normalized sequence
300. Choi JW, Kim Y, Fujino M, et al: Significance of fetal hemoglobin- profiling. J Immunol 1950 192(6):2689–2698, 2014.
containing erythroblasts (F blasts) and the F blast/F cell ratio in 323. Gibson KL, Wu Y-C, Barnett Y, et al: B-cell diversity decreases in old
myelodysplastic syndromes. Leukemia 16(8):1478–1483, 2002. age and is correlated with poor health status. Aging Cell 8(1):18–25,
301. Lopez M, Bonnet-Gajdos M, Reviron M, et al: An acute leukaemia 2009.
augured before clinical signs by blood group antigen abnormalities and 324. Wells RA, Leber B, Buckstein R, et al: Iron overload in myelodysplastic
low levels of A and H blood group transferase activities in erythrocytes. syndromes: a Canadian consensus guideline. Leuk Res 32(9):1338–1353,
Br J Haematol 63(3):535–539, 1986. 2008.